LEADS
Longitudinal Early-Onset Alzheimer's Disease Study

CONTACT DONATE



"When it comes to ending Alzheimer's disease, time is of the essence."

Mary Smith, Philanthropist

Longitudinal Early-Onset Alzheimer's Disease Study (LEADS)

The Longitudinal Early-onset AD Study (LEADS) is funded by the National Institute on Aging (NIA) to address several major gaps in Alzheimer's disease and related dementias research. LEADS is an observational study that will enroll and follow 500 cognitively impaired participants and 100 cognitively normal participants ages 40-64 years at approximately 15 sites in the United States. Clinical, cognitive, imaging, biomarker, and genetic characteristics will be assessed. The primary goal of LEADS is to develop sensitive clinical and biomarker measures for future clinical and research use. Learn More. Join the Fight.

LEADS Principal Investigators

Liana Apostolova

Gil Rabinovici

Brad Dickerson

Maria Carrillo

UCSF Weill Institute for Neurosciences
Memory and Aging Center

MGH 1811

alzheimer's association

NACC

Keck School of Medicine of USC
Alzheimer's Therapeutic Research Institute

Study Goals

- Define early-onset Alzheimer's disease and all its variants
- Understand disease progression
- Derive important clinical, functional and biomarker metrics for clinical trials in the EOAD population
- Understand the impact and unique challenges of younger-onset Alzheimer's
- Identify resources available to assist individuals with younger-onset cognitive impairment

602 consented	43 in screening 445 completed BL	99 CN 332 EOAD 104 EOnonAD	6.2% PCA 5.7% PPA 7.6% Nonamnestic









Schedule of Events

* If LP in CN is unsuccessful at baseline, participants can be re-approached and LP collected at Month 12

\# Only amyloid-positive EOnonAD will receive a tau PET scan at mo 36

$ FDG PET scan for EOnonAD will take place at their next visit

UCSF Weill Institute for Neurosciences
Memory and

LEADS
Longitudinal Early-Onset Alzheimer's Disease Study

LEADS-TU: Scientific rationale

- Strengths:
  - **The cohort** – aggressive disease course, less co-pathology
  - Well-characterized with layers and layers of omics
  - Collecting meaningful trial run-in data
  - EOAD participants are eager to participate